Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), with newly installed CEO, Shawn O’Brien, has adopted a five-by-five strategy that sets objectives for its future growth. “I want to emphasize that this is not guidance, but within five years, we want our dermatology business in Canada to grow from $2-million this year to $50-million, we want to have […]
Tweet Douglas Loe, a health care and biotech analyst with Euro Pacific Canada, discussed the state of the sector today in an interview with BNN’s Pamela Richie. Mr. Loe’s buy recommendations include Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) and Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND). The interview can be accessed here.
Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has named Shawn O’Brien as CEO, effective June 30, succeeding Larry Andrews, who announced in March that he was stepping down. Mr. O’Brien has spent the past 30 years in the pharmaceutical and biotechnology sectors, where he gained extensive global executive leadership experience. He is one of three founders of […]
Tweet Larry Andrews will be stepping down from his position as president and CEO of Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND). To ensure a smooth transition of responsibilities, Mr. Andrews will remain with the company for a period of time while the board undertakes a search process. He will then continue working with Cipher in a consulting […]
Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has reported fourth quarter profit of $17-million or 69 cents a share, compared with $1.5-million or 6 cents in the 2012 quarter. Revenue rose to $12.5-million from $2.9-million. “Strong performance from Absorica, including a sales milestone we achieved in the fourth quarter, helped drive significant revenue and earnings growth in […]
Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has appointed Gerald McDole as chairman, effective immediately, replacing William Garriock, who resigned on Dec. 31, 2013. Mr. McDole has been a member of the Cipher board since 2004. He retired as president and CEO of AstraZeneca Canada’s pharmaceutical operations at the end of 2003.
Tweet Cipher Pharmaceuticals’ (OTCBB:CPHMF; TSX:DND) marketing partner for Absorica has reached a cumulative sales milestone in accordance with the parties’ commercial agreement, triggering a one-time $5-million payment to Cipher. The company said the revenue would be included in its fourth quarter 2013 financial results, which it plans to report in late February. Absorica is an […]
Tweet William Garriock, chairman of Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), is retiring from active business and has resigned as chairman, effective tomorrow. “On behalf of the board, i would like to thank Bill for his service and contributions, and wish him well in retirement,” CEO Larry Andrews said in a statement.
Tweet Third quarter net income for Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) rose to $3.4-million, or 14 cents a share, from $754,000, or 3 cents, in the year earlier quarter. Net revenue climbed to $5.6-million from $2.1-million. “Absorica performed well again in the third quarter, with market share increasing to 17.3% by September from 13.1% in June, […]
Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), in response to questions from shareholders about a Paragraph IV Certification received by its U.S. marketing partner, Ranbaxy Laboratories, has posted on its website some of the most frequently asked questions and Cipher’s response. The Q&A can be accessed here.